Cargando…
Hydrocortisone for Preventing Adverse Drug Reactions to Snake Antivenom: A Meta-Analysis
OBJECTIVE: Pretreatment with hydrocortisone (prehydrocortisone) has been used to protect against adverse drug reactions (ADRs) following antivenom administration after snakebite. However, controversial results have been reported in studies evaluating its efficacy. Herein, we conducted a meta-analysi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054406/ https://www.ncbi.nlm.nih.gov/pubmed/35498377 http://dx.doi.org/10.1155/2022/6151206 |
_version_ | 1784697179329265664 |
---|---|
author | Feng, Jihua Wu, Zimeng Yu, Qiao Li, Hongyuan Ji, Pan Yang, Yanli Zeng, Xiaoliang Zheng, Xiaowen Zhao, Chunling Zhang, Jianfeng |
author_facet | Feng, Jihua Wu, Zimeng Yu, Qiao Li, Hongyuan Ji, Pan Yang, Yanli Zeng, Xiaoliang Zheng, Xiaowen Zhao, Chunling Zhang, Jianfeng |
author_sort | Feng, Jihua |
collection | PubMed |
description | OBJECTIVE: Pretreatment with hydrocortisone (prehydrocortisone) has been used to protect against adverse drug reactions (ADRs) following antivenom administration after snakebite. However, controversial results have been reported in studies evaluating its efficacy. Herein, we conducted a meta-analysis to evaluate the effect of prehydrocortisone on the risk of ADRs. METHODS: We conducted a systematic search of PubMed, Embase, and Cochrane for relevant studies on the literature published up to December 6, 2020, with no language restrictions. Premedications, including hydrocortisone with or without other drugs, were compared with placebo or no premedication. Our primary end point was the risk of ADRs, which was reported as the number of patients who developed ADRs divided by the total number of snakebite patients administered with antivenom separately for the prehydrocortisone and control groups for each study. We evaluated pooled data using of a random-effects model. RESULTS: Among 831 identified studies, 4 were eligible and included in our analysis (N = 1348 participants). Upon combining all eight comparisons from the four selected studies, the overall pooled odds ratio (OR) for ADRs was 0.47 (95% CI 0.19, 1.17; p=0.11; I(2) = 68%). When the analysis was restricted to only articles using hydrocortisone with other drugs, the pooled OR was 0.19 (95% CI 0.05, 0.75; p=0.02; I(2) = 55%). The result was not statistically significant when the analysis was restricted to studies using prehydrocortisone alone, or randomized controlled designs, or cohorts. Our study was limited by heterogeneity, quality, and a paucity of data. CONCLUSIONS: The findings in this study revealed that prehydrocortisone alone was ineffective. However, the substantial beneficial effect of prehydrocortisone combinations with premedications (injectable antihistamines or adrenaline) used against ADRs cannot be excluded. Therefore, the use of prehydrocortisone combinations with premedications (injectable antihistamines or adrenaline) as a prophylaxis may reduce the ADRs to antivenom. |
format | Online Article Text |
id | pubmed-9054406 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-90544062022-04-30 Hydrocortisone for Preventing Adverse Drug Reactions to Snake Antivenom: A Meta-Analysis Feng, Jihua Wu, Zimeng Yu, Qiao Li, Hongyuan Ji, Pan Yang, Yanli Zeng, Xiaoliang Zheng, Xiaowen Zhao, Chunling Zhang, Jianfeng Emerg Med Int Research Article OBJECTIVE: Pretreatment with hydrocortisone (prehydrocortisone) has been used to protect against adverse drug reactions (ADRs) following antivenom administration after snakebite. However, controversial results have been reported in studies evaluating its efficacy. Herein, we conducted a meta-analysis to evaluate the effect of prehydrocortisone on the risk of ADRs. METHODS: We conducted a systematic search of PubMed, Embase, and Cochrane for relevant studies on the literature published up to December 6, 2020, with no language restrictions. Premedications, including hydrocortisone with or without other drugs, were compared with placebo or no premedication. Our primary end point was the risk of ADRs, which was reported as the number of patients who developed ADRs divided by the total number of snakebite patients administered with antivenom separately for the prehydrocortisone and control groups for each study. We evaluated pooled data using of a random-effects model. RESULTS: Among 831 identified studies, 4 were eligible and included in our analysis (N = 1348 participants). Upon combining all eight comparisons from the four selected studies, the overall pooled odds ratio (OR) for ADRs was 0.47 (95% CI 0.19, 1.17; p=0.11; I(2) = 68%). When the analysis was restricted to only articles using hydrocortisone with other drugs, the pooled OR was 0.19 (95% CI 0.05, 0.75; p=0.02; I(2) = 55%). The result was not statistically significant when the analysis was restricted to studies using prehydrocortisone alone, or randomized controlled designs, or cohorts. Our study was limited by heterogeneity, quality, and a paucity of data. CONCLUSIONS: The findings in this study revealed that prehydrocortisone alone was ineffective. However, the substantial beneficial effect of prehydrocortisone combinations with premedications (injectable antihistamines or adrenaline) used against ADRs cannot be excluded. Therefore, the use of prehydrocortisone combinations with premedications (injectable antihistamines or adrenaline) as a prophylaxis may reduce the ADRs to antivenom. Hindawi 2022-04-22 /pmc/articles/PMC9054406/ /pubmed/35498377 http://dx.doi.org/10.1155/2022/6151206 Text en Copyright © 2022 Jihua Feng et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Feng, Jihua Wu, Zimeng Yu, Qiao Li, Hongyuan Ji, Pan Yang, Yanli Zeng, Xiaoliang Zheng, Xiaowen Zhao, Chunling Zhang, Jianfeng Hydrocortisone for Preventing Adverse Drug Reactions to Snake Antivenom: A Meta-Analysis |
title | Hydrocortisone for Preventing Adverse Drug Reactions to Snake Antivenom: A Meta-Analysis |
title_full | Hydrocortisone for Preventing Adverse Drug Reactions to Snake Antivenom: A Meta-Analysis |
title_fullStr | Hydrocortisone for Preventing Adverse Drug Reactions to Snake Antivenom: A Meta-Analysis |
title_full_unstemmed | Hydrocortisone for Preventing Adverse Drug Reactions to Snake Antivenom: A Meta-Analysis |
title_short | Hydrocortisone for Preventing Adverse Drug Reactions to Snake Antivenom: A Meta-Analysis |
title_sort | hydrocortisone for preventing adverse drug reactions to snake antivenom: a meta-analysis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054406/ https://www.ncbi.nlm.nih.gov/pubmed/35498377 http://dx.doi.org/10.1155/2022/6151206 |
work_keys_str_mv | AT fengjihua hydrocortisoneforpreventingadversedrugreactionstosnakeantivenomametaanalysis AT wuzimeng hydrocortisoneforpreventingadversedrugreactionstosnakeantivenomametaanalysis AT yuqiao hydrocortisoneforpreventingadversedrugreactionstosnakeantivenomametaanalysis AT lihongyuan hydrocortisoneforpreventingadversedrugreactionstosnakeantivenomametaanalysis AT jipan hydrocortisoneforpreventingadversedrugreactionstosnakeantivenomametaanalysis AT yangyanli hydrocortisoneforpreventingadversedrugreactionstosnakeantivenomametaanalysis AT zengxiaoliang hydrocortisoneforpreventingadversedrugreactionstosnakeantivenomametaanalysis AT zhengxiaowen hydrocortisoneforpreventingadversedrugreactionstosnakeantivenomametaanalysis AT zhaochunling hydrocortisoneforpreventingadversedrugreactionstosnakeantivenomametaanalysis AT zhangjianfeng hydrocortisoneforpreventingadversedrugreactionstosnakeantivenomametaanalysis |